From 86d20401fb35db18c3d40d5bc31bd962dae96000 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Thu, 19 Mar 2026 13:48:48 +0000 Subject: [PATCH 1/2] extract: 2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA> --- ... net cost impact inflationary through 2035.md | 6 ++++++ ...patients-undermining-chronic-use-economics.md | 6 ++++++ ...-modification-efficacy-combined-approach.json | 9 +++++---- ...le-modification-efficacy-combined-approach.md | 16 +++++++++++++++- 4 files changed, 32 insertions(+), 5 deletions(-) diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index 8a55608b..544662f2 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -113,6 +113,12 @@ Aon's temporal cost analysis shows medical costs rise 23% in year 1 but grow onl International generic competition beginning January 2026 (Canada patent expiry, immediate Sandoz/Apotex/Teva filings) creates price compression trajectory faster than 'inflationary through 2035' assumes. Oral Wegovy launched at $149-299/month (5-8x reduction vs $1,300/month injectable). China/India generics projected at $40-50/month by 2030. Aon 192K patient study shows break-even timing is highly price-sensitive: at $1,300/month, multi-year retention required; at $50-150/month, Aon data suggests cost savings within 12-18 months under capitation. The 'inflationary through 2035' conclusion holds at current US pricing but becomes invalid if international generic arbitrage and oral formulation competition compress effective prices to $50-150/month range by 2030. Scope qualification needed: claim is valid conditional on pricing trajectory assumptions that are now challenged by G7 patent cliff precedent. + +### Additional Evidence (challenge) +*Source: [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]] | Added: 2026-03-19* + +If GLP-1 + exercise combination produces durable weight maintenance (3.5 kg regain vs 8.7 kg for medication alone), and if behavioral change persists after medication discontinuation, then the chronic use model may not be necessary for long-term value capture. This challenges the inflationary cost projection if the optimal intervention is time-limited medication + permanent behavioral change rather than lifetime pharmacotherapy. + --- Relevant Notes: diff --git a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md index f89adfb2..af945c3c 100644 --- a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md +++ b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md @@ -95,6 +95,12 @@ Aon data shows the 80%+ adherent cohort captures dramatically stronger cost redu GLP-1 behavioral adherence failures demonstrate that even breakthrough pharmacology cannot overcome behavioral determinants: patients on GLP-1 alone show same weight regain as placebo without behavior change. This is direct evidence that the 'human constraints' factor (Amodei framework) limits pharmaceutical efficacy independent of drug quality. + +### Additional Evidence (extend) +*Source: [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]] | Added: 2026-03-19* + +Weight regain data shows GLP-1 alone (8.7 kg regain) performs no better than placebo (7.6 kg) after discontinuation, while combination with exercise reduces regain to 3.5 kg. This suggests the low persistence rates may be economically rational from a patient perspective if medication alone provides no durable benefit—patients who discontinue without establishing exercise habits return to baseline regardless of medication duration. + --- Relevant Notes: diff --git a/inbox/queue/.extraction-debug/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.json b/inbox/queue/.extraction-debug/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.json index 20ebfd0d..b2904bbd 100644 --- a/inbox/queue/.extraction-debug/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.json +++ b/inbox/queue/.extraction-debug/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.json @@ -10,16 +10,17 @@ "validation_stats": { "total": 1, "kept": 0, - "fixed": 2, + "fixed": 3, "rejected": 1, "fixes_applied": [ - "glp-1-combined-with-structured-exercise-achieves-60-percent-better-weight-maintenance-than-medication-alone-after-discontinuation.md:set_created:2026-03-18", - "glp-1-combined-with-structured-exercise-achieves-60-percent-better-weight-maintenance-than-medication-alone-after-discontinuation.md:stripped_wiki_link:glp-1-persistence-drops-to-15-percent-at-two-years-for-non-d" + "glp-1-combined-with-structured-exercise-achieves-60-percent-better-weight-maintenance-than-medication-alone-after-discontinuation.md:set_created:2026-03-19", + "glp-1-combined-with-structured-exercise-achieves-60-percent-better-weight-maintenance-than-medication-alone-after-discontinuation.md:stripped_wiki_link:glp-1-persistence-drops-to-15-percent-at-two-years-for-non-d", + "glp-1-combined-with-structured-exercise-achieves-60-percent-better-weight-maintenance-than-medication-alone-after-discontinuation.md:stripped_wiki_link:GLP-1 receptor agonists are the largest therapeutic category" ], "rejections": [ "glp-1-combined-with-structured-exercise-achieves-60-percent-better-weight-maintenance-than-medication-alone-after-discontinuation.md:missing_attribution_extractor" ] }, "model": "anthropic/claude-sonnet-4.5", - "date": "2026-03-18" + "date": "2026-03-19" } \ No newline at end of file diff --git a/inbox/queue/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.md b/inbox/queue/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.md index d9916cbb..b0e625d2 100644 --- a/inbox/queue/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.md +++ b/inbox/queue/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.md @@ -7,13 +7,17 @@ date: 2026-03-01 domain: health secondary_domains: [] format: review -status: unprocessed +status: enrichment priority: high tags: [glp-1, lifestyle-modification, exercise, sarcopenia, muscle-preservation, adherence, weight-regain, obesity] processed_by: vida processed_date: 2026-03-18 enrichments_applied: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"] extraction_model: "anthropic/claude-sonnet-4.5" +processed_by: vida +processed_date: 2026-03-19 +enrichments_applied: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -88,3 +92,13 @@ EXTRACTION HINT: Focus on the GLP-1 alone vs. GLP-1+exercise regain comparison - Up to 50% of adults over 80 experience sarcopenia; aging reduces muscle mass 12-16% independent of weight loss interventions - Tirzepatide may have better muscle preservation profile than semaglutide (preliminary data, not FDA-approved for this indication) - BALANCE model includes lifestyle support component but specific exercise programming details not specified in source + + +## Key Facts +- WHO December 2025 guidelines specifically recommend GLP-1 therapies 'combined with intensive behavioral therapy to maximize and sustain benefits' +- Meta-analysis of 22 RCTs with 2,258 participants found approximately 25% of GLP-1 weight loss is lean mass +- Without exercise, 15-40% of GLP-1 weight loss is lean mass; with resistance training, lean mass loss is substantially reduced +- Up to 50% of adults over 80 experience sarcopenia; aging reduces muscle mass 12-16% independent of weight loss interventions +- At week 52 all intervention groups regained weight after stopping; by week 104: placebo +7.6 kg, liraglutide only +8.7 kg, exercise only +5.4 kg, combination +3.5 kg +- Tirzepatide may have better muscle preservation profile than semaglutide (preliminary data, not FDA-approved for this indication) +- ADA notes new therapies claiming 'enhanced quality of weight loss by improving muscle preservation' but no FDA-approved compounds with proven muscle preservation yet From e700ceb6c6b0600e243c7907815b7c456c2197e0 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Thu, 19 Mar 2026 13:50:45 +0000 Subject: [PATCH 2/2] auto-fix: strip 4 broken wiki links Pipeline auto-fixer: removed [[ ]] brackets from links that don't resolve to existing claims in the knowledge base. --- ...del makes the net cost impact inflationary through 2035.md | 4 ++-- ...etic-obesity-patients-undermining-chronic-use-economics.md | 4 ++-- 2 files changed, 4 insertions(+), 4 deletions(-) diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index 544662f2..0b4f4b8c 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -103,13 +103,13 @@ Value in Health modeling study shows Medicare saves $715M over 10 years with com ### Additional Evidence (challenge) -*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-18* +*Source: 2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction | Added: 2026-03-18* Aon's temporal cost analysis shows medical costs rise 23% in year 1 but grow only 2% after 12 months (vs 6% for non-users), with diabetes patients showing 6-9 percentage point lower cost growth at 30 months. This suggests the 'inflationary through 2035' claim may only apply to short-term payers, while long-term risk-bearers see net savings. ### Additional Evidence (challenge) -*Source: [[2026-03-19-glp1-price-compression-international-generics-claim-challenge]] | Added: 2026-03-19* +*Source: 2026-03-19-glp1-price-compression-international-generics-claim-challenge | Added: 2026-03-19* International generic competition beginning January 2026 (Canada patent expiry, immediate Sandoz/Apotex/Teva filings) creates price compression trajectory faster than 'inflationary through 2035' assumes. Oral Wegovy launched at $149-299/month (5-8x reduction vs $1,300/month injectable). China/India generics projected at $40-50/month by 2030. Aon 192K patient study shows break-even timing is highly price-sensitive: at $1,300/month, multi-year retention required; at $50-150/month, Aon data suggests cost savings within 12-18 months under capitation. The 'inflationary through 2035' conclusion holds at current US pricing but becomes invalid if international generic arbitrage and oral formulation competition compress effective prices to $50-150/month range by 2030. Scope qualification needed: claim is valid conditional on pricing trajectory assumptions that are now challenged by G7 patent cliff precedent. diff --git a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md index af945c3c..7c183635 100644 --- a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md +++ b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md @@ -85,13 +85,13 @@ Weight regain data shows that even among patients who complete treatment, GLP-1 ### Additional Evidence (extend) -*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-18* +*Source: 2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction | Added: 2026-03-18* Aon data shows the 80%+ adherent cohort captures dramatically stronger cost reductions (9 percentage points lower for diabetes, 7 points for weight loss), confirming that adherence is the binding variable for economic viability. The adherence-dependent savings pattern means low persistence rates eliminate cost-effectiveness even when clinical benefits exist. ### Additional Evidence (extend) -*Source: [[2026-03-19-vida-ai-biology-acceleration-healthspan-constraint]] | Added: 2026-03-19* +*Source: 2026-03-19-vida-ai-biology-acceleration-healthspan-constraint | Added: 2026-03-19* GLP-1 behavioral adherence failures demonstrate that even breakthrough pharmacology cannot overcome behavioral determinants: patients on GLP-1 alone show same weight regain as placebo without behavior change. This is direct evidence that the 'human constraints' factor (Amodei framework) limits pharmaceutical efficacy independent of drug quality.